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Abstract
Background: Those receiving tenofovir/emtricitabine (TDF-FTC) had greater bone loss compared with abacavir/lamivudine
(ABC-3TC) in a randomized simplification trial (STEAL study). Previous studies associated increased bone turnover and bone
loss with initiation of antiretroviral treatment, however it is unclear whether change in bone mineral density (BMD) was a
result of specific drugs, from immune reconstitution or from suppression of HIV replication. This analysis determined
predictors of BMD change in the hip and spine by dual-energy x-ray absorptiometry in virologically suppressed participants
through week 96.
Methodology/Principal Findings: Bone turnover markers (BTMs) tested were: formation [bone alkaline phosphatase,
procollagen type 1 N-terminal propeptide (P1NP)]; resorption (C-terminal cross-linking telopeptide of type 1 collagen [CTx]);
and bone cytokine-signalling (osteoprotegerin, RANK ligand). Independent predictors of BMD change were determined
using forward, stepwise, linear regression. BTM changes and fracture risk (FRAXH) at week 96 were compared by t-test.
Baseline characteristics (n=301) were: 98% male, mean age 45 years, current protease-inhibitor (PI) 23%, tenofovir/abacavir-
naı ¨ve 52%. Independent baseline predictors of greater hip and spine bone loss were TDF-FTC randomisation (p#0.013),
lower fat mass (p-trend#0.009), lower P1NP (p=0.015), and higher hip T score/spine BMD (p-trend#0.006). Baseline PI use
was associated with greater spine bone loss (p=0.004). TDF-FTC increased P1NP and CTx through Wk96 (p,0.01). Early
changes in BTM did not predict bone loss at week 96. No significant between-group difference was found in fracture risk.
Conclusions/Significance: Tenofovir/emtricitabine treatment, lower bone formation and lower fat mass predicted
subsequent bone loss. There was no association between TDF-FTC and fracture risk.
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Introduction
Highly active antiretroviral therapy (HAART) significantly
improves survival and quality of life for individuals with human
immunodeficiency virus (HIV) infection. However, clinical
management challenges now include several disorders associated
with aging, including higher prevalence of low bone mineral
density (BMD) [1] and higher rates of fractures [2] than in
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38377adults without HIV. Prospective studies, mostly small and/or
non-randomized, have generally found that ART initiation
reduced BMD by 1% to 5% over 1 to 2 years (reviewed in [3])
although this initial short-term bone loss may not be ongoing
[4]. These rates of bone loss appear greater than those expected
in healthy men, being more similar to those in post-menopausal
women [5]. Therapy with tenofovir (TDF) has been associated
with greater reductions in BMD than with stavudine or abacavir
(ABC) [6,7,8]. Bone metabolism can be assessed by measuring
serum bone turnover markers (BTMs), comprising proteins
synthesized during bone formation, bone matrix proteins, and
bone collagen degradation products released during bone
resorption. High levels of BTMs have been found to predict
fractures independently of BMD in post-menopausal women [9]
and elderly men [10]. Furthermore, as BTMs can provide a
more dynamic estimate of bone metabolism in shorter
timescales than BMD, these markers have been suggested as
additional tools for more rapid assessment of bone disease [11].
Interleukin-1 (IL-1), IL-6, and tumour necrosis factor-alpha
(TNF-a) can all increase bone resorption [12], and their
circulating levels predict changes in BMD in HIV-uninfected
adults [13]. Despite undetectable HIV viral load on ART, HIV-
infected individuals have significantly higher levels of IL-6
compared with the general population [14].
BTMs have been found to be elevated in ART-treated
compared with untreated patients in some cross-sectional studies
[15,16,17]. In a trial of ART-naive patients, those randomized to
TDF-emtricitabine (FTC) had greater bone loss and greater BTM
increases over 24 weeks than those randomised to ABC-
lamivudine (3TC) [7]. Other studies have shown that early
increases in bone resorption were associated with BMD decreases
and were followed by increased bone formation in ART-naı ¨ve
adults, but it is not possible from these data to determine whether
the BMD and BTM changes were a result of specific drugs, from
immune reconstitution or from suppression of HIV replication
[18,19].
In the STEAL study, virologically suppressed patients
randomized to simplify dual nucleoside analogue reverse
transcriptase inhibitor (NRTI) therapy to coformulated TDF-
FTC had greater bone loss over 96 weeks than those
randomised to co-formulated ABC-3TC [20]. This analysis
aimed to explore STEAL bone outcomes in more detail and to
determine predictors of BMD change. We hypothesized that
some patients might be at greater risk of TDF-related BMD loss
over 96 weeks and that this greater loss might be predicted by
either baseline or on-study BTM levels.
Methods
Study Design
STEAL was an open-label, prospective, randomized, non-
inferiority study that compared simplification of current NRTIs to
fixed-dose combination TDF-FTC or ABC-3TC over 96 weeks in
357 adults with plasma HIV viral load ,50 copies/ml [20]. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Protocol S1, Protocol S2
and Checklist S1.
Ethics
The study was approved by each site’s Human Research and
Ethics Committee (30 sites) and registered at Clinicaltrials.gov
(NCT00192634). Each participant signed a written informed
consent before enrolment.
Bone Mineral Density and Laboratory Markers
Dual-energy X-ray absorptiometry (DXA) of the lumbar spine
and right hip were performed for each participant at the same
imaging facility on the same bone densitometer, at baseline, week
48, and week 96, using a standardized protocol. BMD scans were
not centrally analysed. DXA instruments varied between sites
(GE-Lunar in 72% of sites); randomization was stratified by site,
and therefore by model of DXA scanner.
Plasma and serum samples were collected at baseline and at
weeks 12, 24, 48, 72 and 96 (following a 10-hour overnight fast,
except at week 12) and stored at –70uC. Markers of bone
resorption (C-terminal cross-linking telopeptide of type 1 collagen,
[bCTX]; bone formation (procollagen type 1 N-terminal propep-
tide [P1NP]; bone-specific alkaline phosphatase,[BALP]) and
regulators of bone turnover (osteoprotegerin [OPG] and receptor
activator of nuclear factor kappa ligand [RANKL]) were
evaluated. bCTX and P1NP were assayed by an electrochemilu-
minescence immunoassay (E170 immunoassay analyzer; Roche,
Mannheim, Germany; reference ranges bCTX 170–600 ng/L,
P1NP 16.3–78.2 ug/L). BALP, OPG and RANKL were assayed
by Immunoenzymetric Assay (Manual with Plate Reader;
Immunodiagnostic Systems, Boldon, United Kingdom; reference
ranges BALP 8–21.3 ug/L, OPG ,30 pmol/L, RANKL
,100 pmol/L). The following were assessed at baseline only:
Interleukin-6 by ELISA R&D Systems Human IL-6 (reference
range 0.447–9.96 pg/ml); oestradiol by electrochemiluminescence
(E170 immunoassay analyzer; Roche, reference range 50–
200 pmol/L); free testosterone using total testosterone and sex
hormone-binding globulin (Vermeulen formula [20]); and 25-
hydroxy vitamin D by competitive chemiluminescence (Liasion;
DiaSorin, Inc., Stillwater, MN, USA).
BTMs were batch-tested after study completion in one
laboratory. Coefficients of variation were within accepted standard
limits. The 10-year risks of osteoporotic and hip fractures were
estimated using the FRAXH UK algorithm of the World Health
Organization (WHO) [21]. The proportion of participants above
the threshold recommended for intervention with antiresorptive
therapy was determined according to the US National Osteopo-
rosis Foundation (NOF) guidelines [22]. For the analysis of
clinically relevant low BMD, low BMD was defined as T-score
,21 in accordance with WHO diagnostic thresholds [23].
Statistical Analysis
Statistical analysis was conducted on the per protocol (PP)
population, comprising all participants with BMD data and on
randomized therapy at each time point. A PP approach was used
to explore biological mechanisms of BMD change in response to
study drug exposure. A pre-defined secondary analysis of this
substudy was performed on the subpopulation that was not
receiving ABC or TDF at study entry (‘‘TDF/ABC-naı ¨ve’’).
Randomization was stratified by baseline NRTI use (TDF without
ABC, ABC without TDF, or other), current protease inhibitor use,
and study site. Absolute change in BMD at the lumbar spine and
hip was the primary outcome of interest. Percent change was
summarised as a secondary outcome.
The associations between baseline covariates (including demo-
graphic, HIV-related factors, ART, body composition, BTMs,
bone remodelling regulators, sex hormones, vitamin D and IL-6;
Table 1) and changes in BTMs from baseline to week 12, and
absolute changes in hip and lumbar spine BMD to week 96 were
analysed using linear regression. Three patients, all on TDF-FTC,
started anti-resorptive therapy after week 48 and were included in
the analysis. However, data on use of alcohol, glucocorticoids,
vitamin D and calcium supplementation that can affect BMD were
Bone Loss and Bone Turnover in HIV
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stepwise methods. Predictors that achieved a p-value ,0.08 in
univariate analysis (more conservative than 0.1) were assessed for
inclusion in the multivariable model. Randomized groups were
compared for changes in BTMs and FRAXH results by t-test at 48
weeks (BTMs only) and 96 weeks. Interaction between baseline
exposure to TDF or ABC and randomized arm in predicting
BTMs was tested using linear regression for the interaction term.
Contingency-table and chi-square tests were used for analysis of
proportions warranting antiresorptive-therapy (US NOF guide-
lines) and for incidence of low BMD. Sensitivity analysis was
conducted for FRAXH results for participants who were at $40
years of age at baseline and for proportions warranting anti-
resorptive therapy (US NOF guidelines) for participants who are at
$50 years of age at baseline. Pearson’s correlation was used to
assess associations between changes in BTMs across the entire
study population.
Statistical significance was defined as a 2-sided a of 0.05. All
analyses of the main BMD and BTM outcomes were determined a
priori and were hypothesis driven. No adjustment was made for
multiple comparisons. Statistical analyses were performed with
STATA, version 10.1 (Statacorp).
Results
Of 357 participants enrolled in the parent study, 18 discontin-
ued ABC-3TC and 16 discontinued TDF-FTC by week 96. An
additional 22 participants (14 on ABC-3TC and 8 on TDF-FTC)
did not have data for hip and spine BMD change from baseline to
week 96. Therefore, the analysed per-protocol population
comprised the remaining 301 participants (84% of main study
population). Baseline characteristics of the population analysed
were similar to main study [19] and well balanced between arms
(Tables 1, 2).
Bone Mineral Density Change from Baseline
At week 96, the absolute change from baseline in hip BMD in
the ABC-3TC group was 0.004 g/cm
2 versus 20.007 g/cm
2 in
the TDF-FTC group (treatment difference 0.01 g/cm
2 (95%
confidence interval [CI] 0.003 to 0.018; p=0.006). For lumbar
spine, the absolute BMD change over 96 weeks in ABC-3TC
group was 0.008 g/cm
2 and 20.005 g/cm
2 in the TDF-FTC
group (treatment difference 0.01 g/cm
2 (95% CI 0.002 to 0.024;
p=0.016). BMD changes in the ‘TDF/ABC-naı ¨ve’ subpopulation,
were of similar magnitude (Table 2, Figure 1).
Baseline Predictors of Change in Bone Mineral Density
Baseline covariates significantly associated with greater decline
in hip BMD over 96 weeks in multivariable analysis were TDF-
FTC randomisation (p=0.001), lower fat mass (p trend=0.009),
lower P1NP (p=0.015), and higher hip T-score (p trend=0.006).
Baseline predictors of greater decline in spine BMD were TDF-
FTC randomisation (p=0.013), lower fat mass (p trend=0.005),
protease inhibitor use (p=0.004), and higher spine BMD
(p=0.001; Table 3).
Bone Turnover Markers
Significant differences in absolute changes in bone resorption
and formation markers were seen after baseline between treatment
groups. In the PP population, bCTx (bone resorption marker)
increased significantly at week 12 in TDF-FTC compared to ABC-
3TC arm (treatment difference 71.8 ng/L (95% CI 40.2 to 103.4;
p,0.001)) and then remained stable through week 96. Similarly,
increases in bone formation markers were greater with TDF-FTC
Table 1. Baseline characteristics.
Baseline Characteristic ABC-3TC (n=147) TDF-FTC (n=154)
Age (years) 45.868.7 44.768.3
Male (%) 99 97
Ethnicity - white (%) 84 86
HIV duration (years) 9.965.8 10.566.1
CD4+ count (cells/mm
3)6 2 3 6300 6046262
IL6 (pg/ml) 2.262.0 1.961.4
NRTI exposure
Prior ABC (n, %) 28 (19) 29 (19)
Prior TDF (n, %) 42 (29) 45 (29)
Naive to ABC and TDF (n,%) 77 (52) 80 (52)
NRTI duration (years) 5.763.4 5.763.5
PI duration (years) 2.062.7 1.962.7
NNRTI duration (years) 3.562.8 3.662.8
Current protease inhibitor (%) 23 24
Anthropometric factors
Body mass index (kg/m2) 24.763.5 24.863.6
Fat mass (g) 1581366970 1612867901
BMD
Right hip (g/cm
2) 1.0260.13 1.0260.14
Spine (g/cm
2) 1.1860.16 1.1960.16
Bone resorption
bCTx (ng/L) 240.06148.1 263.96145.4
Bone formation
BALP (mg/L) 20.2610.2 19.8611.6
P1NP (mg/L) 53.3623.1 57.0622.6
Bone regulation
OPG (pmol/L) 3.961.3 3.861.1
RANKL (pmol/L) 0.260.3 0.360.4
Sex hormones
Total testosterone (nmol/l) 17.567.7 17.767.7
Free testosterone (pmol/L) 295.96123.6 291.06125.8
25-hydroxy vitamin D (nmol/L) 71.2630.4 67.5630.0
Oestradiol (pmol/L) 91.5639.5 90.6634.4
Ten-Year Fracture Risk
a
Major OP fracture risk 3.360.1 3.360.1
Hip fracture risk 0.660.1 0.660.1
Note. Results are expressed as mean 6 standard deviation or %.
Abbreviations: ABC-3TC, abacavir-lamivudine; BALP, bone-specific alkaline
phosphatase; bCTx, C-terminal cross-linking telopeptide of type 1 collagen;
BMD, bone mineral density; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; OP, osteoporotic; OPG, osteoprotegerin; P1NP, procollagen type 1
N-terminal propeptide; RANKL, Receptor Activator of Nuclear Factor Kappa
Ligand; TDF-FTC, tenofovir-emtricitabine.
aAccording to FRAXH Scores Computed with BMD.
doi:10.1371/journal.pone.0038377.t001
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(difference 8.79 mg/L [95% CI 5.48 to 12.10; p,0.001]) and
remained stable thereafter. Another formation marker, BALP, was
significantly different from week 24 onwards with greater increases
with TDF-FTC than with ABC-3TC (difference 2.83 mg/L [95%
CI 0.59 to 5.07; p=0.014]) (Table 3, Figure 2). There was no
significant, between-group difference in OPG or RANKL. Similar
results were found in the ABC/TDF-naive subpopulation (data
not shown). Changes in the bone resorption marker, bCTx, were
correlated at all time points with changes in P1NP, a formation
marker (r.0.30, p,0.001). Changes in BALP were correlated
with changes in bCTx from week 24 onwards (r.0.15, p,0.014)
except at week 48.
Clinical Implications
There was no difference in FRAXH scores at 96 weeks either
within each group or between groups. The FRAXH scores at week
96 for ten-year fracture risk for major osteoporotic fracture were:
3% for both ABC-3TC and TDF-FTC; hip fracture 0.4% with
ABC-3TC vs. 0.5% with TDF-FTC in the PP population. There
was no significant difference in the proportion (0.6% in ABC-3TC
vs. 2.5% in TDF-FTC) of participants who met the NOF
guidelines criteria for treatment by week 96. Similarly, there was
no significant between-group difference in the incidence of
participants who developed low hip BMD (T score #21; 3.8%
in ABC-3TC vs. 8.7% in TDF-FTC) or low spine BMD (3.8% in
ABC-3TC vs. 7.4% in TDF-FTC) by week 96.
Discussion
Small, yet significant differences between TDF-FTC and ABC-
3TC in changes in absolute BMD values were found in our study,
with greater bone loss in the TDF-FTC group over 96 weeks.
Independent predictors for bone loss at both the hip and lumbar
spine included TDF-FTC randomisation and lower baseline fat
Figure 1. Mean change from baseline to week 96 in right hip (A,B) and lumbar spine bone mineral density (C,D) by study
population and randomised arm (abacavir-lamivudine vs. tenofovir-emtricitabine). The right hand side of each graph shows the mean
percent change in BMD at weeks 48 and 96. Note. p values from t-test comparing mean change from baseline to study week of interest in
randomized arms. Error bars represent 1 standard deviation from the mean.Abbreviations: ABC/3TC, abacavir/lamivudine; TDF/FTC, tenofovir/
emtricitabine.
doi:10.1371/journal.pone.0038377.g001
Bone Loss and Bone Turnover in HIV
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38377mass. Further, lower serum P1NP (bone formation marker)
predicted greater hip bone loss, while protease inhibitor use at
baseline predicted greater spine bone loss. BTMs significantly
increased from week 12 with TDF-FTC, but their early changes
(at week 12) did not predict subsequent bone loss. The clinical
relevance of these changes is unknown.
Both the ASSERT study and ACTG 5224s, in ART-naive
adults, found similar results over 48 weeks, showing greater
increases in bone turnover [7] and decrease in BMD [7,8] in
participants randomised to TDF-FTC compared with ABC-3TC.
The greater BMD loss observed in ASSERT compared with our
study may in part be due to different populations (ASSERT
participants were younger, ART-naı ¨ve, more immunodeficient
and more ethnically diverse).
The association found between protease inhibitor use and spine
bone loss confirms findings by other investigators [8,24]. The spine
comprises mainly trabecular bone, which is affected earlier than
cortical bone (femoral neck) by high bone turnover [25]. Protease
inhibitors can reduce calcium deposition and alkaline phosphatase
expression in osteoblasts [26], both markers of osteoblast
differentiation. This effect may explain why PINP, a bone
formation marker primarily expressed during osteoblast prolifer-
ation, was more sensitive in detecting TDF-FTC effects on bone
loss. We showed PINP increased with TDF-FTC treatment, while
BAP did not, and lower PINP levels predicted greater bone loss
from the hip, but not the spine. The mechanisms underlying the
effect of TDF on increasing bone loss have not been clearly
established, although recent in vitro studies suggest TDF may alter
gene expression in both osteoblasts and osteoclasts [27,28].
Furthermore, in similar settings without viraemia, a pre-exposure
prophylaxis study found that initiation of TDF is also associated
with bone loss, though bone turnover was not reported [29].
Higher baseline hip T-score and spine BMD predicted greater
bone loss from the hip and spine, respectively in our study, an
observation reported previously in the setting of allogeneic bone
marrow transplantation [30]. This finding provides reassurance
that patients with low BMD are not particularly at risk of greater
bone loss when receiving TDF. The findings regarding the effect of
lower fat mass on bone loss are supported by similar evidence in
the general population, suggesting a link between body compo-
sition and bone density and the protective role of obesity on bone
[31]. Other studies in HIV-infected adults have reported that low
weight and BMI were associated with low BMD [32,33], but we
did not observe this association.
BTM levels increase following ART initiation [7,19]. One study
found reductions in bone formation with increased resorption,
which increased with more advanced untreated HIV infection,
suggesting ‘‘uncoupling’’ of the usually well regulated processes of
bone resorption and formation [17]. After ART initiation, a
‘‘recoupling’’ of bone formation and resorption appears to occur,
albeit with higher levels of bone turnover [17]. It is not clear
whether the early changes in BTMs after ART initiation reflect the
effects of specific ART drugs, HIV suppression or immune
reconstitution. Our study is the first to report BTM changes with
ART switching in stable, virologically suppressed individuals.
Table 3. Baseline covariates assessed in the multivariate model of change in right hip and lumbar spine bone mineral density over
96 weeks.
Right hip Multivariate Analysis Lumbar Spine Multivariate Analysis
Baseline Covariate Coef.
95% confidence
interval P P trend Coef.
95% Confidence
Interval P P trend
TDF-FTC randomisation 20.01 20.02 to 20.01 0.001 20.01 20.02 to 20.00 0.013
Right Hip T score wk0– WHO categories:
#22.5* reference
22.5,t,21.0 20.02 20.04 to 0.01 0.166
$21.0 20.03 20.05 to 20.00 0.031 0.006
Fat mass wk0 - quartiles:
1110–10590 g 20.015 20.03 to 20.00 0.005 20.02 20.03 to 20.00 0.023
10591–15428 g 20.004 20.02 to 0.01 0.424 20.01 20.02 to 0.01 0.271
15429–20942 g 20.002 20.01 to 0.01 0.711 0.01 20.01 to 0.02 0.489
20943–46433 g* reference 0.009 reference 0.005
missing 20.049 20.11 to 0.02 0.134 0.01 20.08 to 0.11 0.787
P1NP wk0 0.001 0.00 to 0.00 0.015
PI at Baseline 20.02 20.03 to 20.01 0.004
L1–L4 Spine BMD wk0 - quartiles:
0.788–1.061* reference
1.062–1.180 20.02 20.03 to 20.00 0.018
1.181–1.292 20.01 20.03 to 0.00 0.057
1.293–1.798 20.03 20.04 to 20.01 ,0.001 0.001
Note. Baseline covariates from the univariate analysis that were assessed in multivariate model and not included in the final model for the hip were N(t)RTI duration,
NRTI duration, femoral BMD, free testosterone, P1NP change from baseline to week 12, CTx change from baseline to week 12; for the spine: PI duration, NRTI duration,
alkaline phosphatase, spine T score, hip T score;
Abbreviations: PI, protease inhibitor; P1NP, procollagen type 1 N-terminal propeptide; TDF-FTC, Tenofovir-Emtricitabine.
doi:10.1371/journal.pone.0038377.t003
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changes can predict BMD change with ART. Changes in markers
to week 12 were not associated with BMD decrease at week 96.
Only lower baseline levels of one bone formation marker (P1NP)
predicted greater bone loss at the hip. BTMs were significantly
increased in the TDF-FTC arm compared with ABC-3TC, as seen
in the ASSERT study [7]. These changes occurred early in the
study (week 12) and bone turnover remained significantly higher in
those randomized to TDF-FTC compared with ABC-3TC
through 96 weeks. This is in contrast to the ASSERT study
findings of similar bone resorption marker levels from week 48
onwards. Both studies show that formation and resorption
remained coupled during study follow-up.
Although we could not assess fracture rates in this study, we
explored other clinical implications by evaluating the 10-year
fracture risk using the FRAXH algorithm and the incidence of
participants above the FRAX threshold recommended for
antiresorptive therapy according to NOF guidelines. No significant
difference was found between TDF-FTC and ABC-3TC, even in
analyses restricted to the older patients for which FRAX and NOF
guidelines were designed, implying limited clinical significance. It
is likely, however, that in addition to the small changes in BMD,
the study was underpowered to detect significant risk differences
between the groups. In addition, the FRAX equation requires
additional clinical data not collected in STEAL (prior personal
history of fracture, prior rheumatoid arthritis, family history of hip
fracture, alcohol use). Therefore, the fracture risk may have been
underestimated. The NOF guidelines were developed and
validated in postmenopausal women and men aged at least 50
years, so the NOF estimates derived in this study should be viewed
more in terms of the difference between groups rather than the
absolute risk in each group. Lastly, FRAX and the NOF guidelines
have not been validated in HIV-infected populations.
Our study has limitations. Our cohort was at low overall risk
(average age 45 years, predominantly male) for bone-related harm
as demonstrated by small BMD changes, with limited statistical
power to determine predictors of change. In addition, as
participants were on different regimens when entering the study,
the sizes of the different sub-populations according to their
baseline NRTI and PI agents were small, with attenuated
statistical power for secondary analyses. The relatively short
duration of the study and the small sample size did not allow for
investigation of fractures and a possible association with the risk
factors found. DXA scans were not centrally read to minimise
measurement variability. An earlier time-point (e.g. 4 weeks) for
BTM measurement may have provided more insight into the early
pathophysiological effect of ART on bone metabolism.
Our study suggests that HIV-infected adults may benefit from
assessment of risk factors associated with fractures prior to
switching to TDF-FTC because of the associated higher bone
turnover, and adults with a low fat mass are at higher risk for bone
loss. In addition, measurement of P1NP might be useful in
Figure 2. Mean change from baseline to week 96 in bone turnover markers by randomised arm (abacavir-lamivudine vs. tenofovir-
emtricitabine). Note. Error bars represent 1 standard deviation from the mean (a) BALP, bone-specific alkaline phosphatase; (b) P1NP,
procollagen type 1 N-terminal propeptide; (c) bCTx, C-terminal cross-linking telopeptide of type 1 collagen; (d) OPG, osteoprotegerin; ABC/3TC,
abacavir/lamivudine; TDF/FTC, tenofovir/emtricitabine. There was no significant between-group difference at any time point for RANK.
doi:10.1371/journal.pone.0038377.g002
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confirmation in larger studies.
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